TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7693504

Group type: EXPERIMENTAL
Intervention: terfenadine, 180 mg, by mouth
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ipratropium bromide, 0.5 mg, nebulized
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: both active drugs together (terfenadine and ipratropium bromide)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo preparations (by mouth and by nebulizer)
Number of subjects: 10
Study: 3536171

Group type: EXPERIMENTAL
Intervention: Low dose sublingual therapy with house dust mite
Number of subjects: 18
Study: 29420194

Group type: EXPERIMENTAL
Intervention: RT with lid manipulation (LM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: RT without lid manipulation (LM)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry (GAT)
Number of subjects: 103
Study: 26856586

Group type: EXPERIMENTAL
Intervention: SpineJack® (SJ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Balloon Kyphoplasty (BKP)
Number of subjects: 30
Study: 24958751

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 2137
Study: 21512799

Group type: EXPERIMENTAL
Intervention: General fitness training performed as leg‐bicycling (GFT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Specific strength training of the neck/shoulder muscles (SST)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Reference intervention without physical exercise
Number of subjects: 39
Study: 20368520

Group type: COMPARATOR
Intervention: UFH 70 U/kg
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: M118 50 IU/kg IV
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: M118 75 IU/kg IV
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: M118 100 IU/kg IV
Number of subjects: 503
Study: 19010733

Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS) for primary BCC
Number of subjects: 612

Group type: COMPARATOR
Intervention: Surgical excision for primary BCC
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Mohs' micrographic surgery (MMS) for recurrent BCC
Number of subjects: 612

Group type: COMPARATOR
Intervention: Surgical excision for recurrent BCC
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of MMS for primary BCC
Number of subjects: 612

Group type: COMPARATOR
Intervention: Cost-effectiveness of surgical excision for primary BCC
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of MMS for recurrent BCC
Number of subjects: 612

Group type: COMPARATOR
Intervention: Cost-effectiveness of surgical excision for recurrent BCC
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio for primary BCC
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Incremental cost-effectiveness ratio for recurrent BCC
Number of subjects: 612
Study: 15755834

Group type: COMPARATOR
Intervention: Wheat products fortified with 0 mg Zn (group Zn-0)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Wheat products fortified with 3 mg Zn (group Zn-3)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Wheat products fortified with 9 mg Zn (group Zn-9)
Number of subjects: 41
Study: 12585143

Group type: EXPERIMENTAL
Intervention: Wuzi Yanzong Pill (WZYZP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10029942

Group type: EXPERIMENTAL
Intervention: Gillet test
Number of subjects: 41
Study: 8748919

Group type: EXPERIMENTAL
Intervention: Fibrin sealant for embryo transfer (ET)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Mobilization after ET
Number of subjects: 211
Study: 2328178

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.1, 0.2, 0.4 or 1 mg kg‐1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Edrophonium with enflurane 2% discontinued
Number of subjects: 100
Study: 6788282

Group type: EXPERIMENTAL
Intervention: Aluminium sucrose biscuits
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo biscuits
Number of subjects: 6

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 6
Study: 31676389

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g/day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30188800

Group type: EXPERIMENTAL
Intervention: SRA (simple resistance activities)
Number of subjects: 19

Group type: COMPARATOR
Intervention: SIT (five hours uninterrupted sitting)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SRA
Number of subjects: 19
Study: 26720202

Group type: EXPERIMENTAL
Intervention: Protocol 2 (test bolus method)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Protocol 1 (fixed delay time scan method)
Number of subjects: 110
Study: 24468043

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balloon-occluded retrograde transvenous obliteration (BRTO)
Number of subjects: 50
Study: 22768888

Group type: EXPERIMENTAL
Intervention: Glucose pentagon model (GPM)
Number of subjects: 108
Study: 19969485

Group type: EXPERIMENTAL
Intervention: Autogenous coronoid process pedicled on temporal muscle grafts (ACPTMG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Autogenous free coronoid process grafts (AFCPG)
Number of subjects: 48
Study: 17005577

Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps (with electrocoagulation)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cold biopsy forceps (without electrocoagulation)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cold biopsy forceps
Number of subjects: 39
Study: 15803263

Group type: EXPERIMENTAL
Intervention: Job performance with heavy physical exertion
Number of subjects: 108

Group type: COMPARATOR
Intervention: Expected risk without heavy physical exertion
Number of subjects: 108

Group type: COMPARATOR
Intervention: Expected cardiac events related to job performance
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Relative risk for observed cardiac events
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Relative risk for expected events compared to basal risk
Number of subjects: 108
Study: 11877616

Group type: EXPERIMENTAL
Intervention: Arthroscopic measurement of inferior humeral displacement at 15 degrees of forward flexion and 70 degrees of abduction and neutral rotation.
Number of subjects: 143
Study: 9643568

Group type: EXPERIMENTAL
Intervention: LRP overexpression (LRP+) defined by expression of LRP 56 in at least 20% of marrow blasts.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: LRP overexpression (LRP+)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Anthracycline‐AraC intensive chemotherapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low dose AraC
Number of subjects: 41
Study: 9138874

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (laparoscopy)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Laparotomy (control)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 192
Study: 3063328

Group type: EXPERIMENTAL
Intervention: Two-antibody depleted grafts (T10B9 and T12A10)
Number of subjects: 34

Group type: COMPARATOR
Intervention: One-antibody depleted grafts (T10B9)
Number of subjects: 34
Study: 30307720

Group type: EXPERIMENTAL
Intervention: Mini dental implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional dental implants
Number of subjects: 0
Study: 27649676

Group type: EXPERIMENTAL
Intervention: BIFICO treatment (oral admission)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Control group (primary disease treatment alone)
Number of subjects: 215
Study: 24885377

Group type: EXPERIMENTAL
Intervention: Percutaneous catheter ablation (n = 100)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Surgical ablation (n = 50)
Number of subjects: 150
Study: 22335234

Group type: EXPERIMENTAL
Intervention: Electrical stimulation with different pulse types at 38.2°C and 40.7°C heat intensity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Biphasic continuous stimulation at 7 Hz
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Increasing heat during electrical stimulation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Higher stimulation intensity
Number of subjects: 14
Study: 20359612

Group type: EXPERIMENTAL
Intervention: Brief advice plus exhaled CO analysis
Number of subjects: 578

Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 578
Study: 18322901

Group type: EXPERIMENTAL
Intervention: ARMOR training
Number of subjects: 8

Group type: COMPARATOR
Intervention: EMG‐triggered neuromuscular electrical stimulation (EMG‐NMES)
Number of subjects: 8

Group type: COMPARATOR
Intervention: EMG‐NMES
Number of subjects: 8
Study: 15983319

Group type: EXPERIMENTAL
Intervention: Statin therapy (simvastatin 20 mg daily after cerivastatin 0.4 mg daily)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 250
Study: 15138154

Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combined GHRH and arginine
Number of subjects: 8
Study: 10699602

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks followed by a maintenance dose of 240 mg every month (n = 458)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Total androgen ablation (TAA) via bilateral orchiectomy or triptorelin 3.75 mg every month combined with flutamide 250 mg three times daily (n = 457)
Number of subjects: 915
Study: 9382545

Group type: EXPERIMENTAL
Intervention: Continuous hepatic arterial infusion of 5‐FU (360 mg/m2/day x 5 days/week x 4 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of 5‐FU (360 mg/m2/day x 2 weeks)
Number of subjects: 14
Study: 8334911

Group type: EXPERIMENTAL
Intervention: Fundus‐III (a composite herbal recipe for Huoxue‐Huayu)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 80
Study: 3962571

Group type: EXPERIMENTAL
Intervention: Double-barrelled 16F-Argyle Salem sump tube, length 120 cm, size 16 CH
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Single-barrelled stomach tube, length 80 cm, size 25 CH
Number of subjects: 80
Study: 2662100

Group type: EXPERIMENTAL
Intervention: Pneumatic retinopexy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Scleral buckling
Number of subjects: 198
Study: 31992367

Group type: EXPERIMENTAL
Intervention: Acupuncture at EX-HN3, LI20, and EX-HN8 thrice per week for a total of 12 sessions plus acupoint application at DU14, BL13, EX-BI, and RN22
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sham AAP
Number of subjects: 120
Study: 31492651

Group type: EXPERIMENTAL
Intervention: ozanimod 1.0 mg
Number of subjects: 1346

Group type: EXPERIMENTAL
Intervention: ozanimod 0.5 mg
Number of subjects: 1346

Group type: COMPARATOR
Intervention: interferon beta-1a
Number of subjects: 1346
Study: 28987625

Group type: EXPERIMENTAL
Intervention: 8% arginine‐containing toothpaste
Number of subjects: 12

Group type: COMPARATOR
Intervention: Arginine-free toothpaste (control)
Number of subjects: 12
Study: 25880207

Group type: EXPERIMENTAL
Intervention: Ripasudil, 0.4% combined with Timolol, 0.5%
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Ripasudil, 0.4% combined with Latanoprost, 0.005%
Number of subjects: 413
Study: 23840043

Group type: EXPERIMENTAL
Intervention: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) with electroporation
Number of subjects: 0

Group type: COMPARATOR
Intervention: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) without electroporation
Number of subjects: 0
Study: 21612471

Group type: EXPERIMENTAL
Intervention: Early locomotor training (treadmill with body-weight support, started 2 months after stroke)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Late locomotor training (treadmill with body-weight support, started 6 months after stroke)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Home-exercise program (managed by a physical therapist, started 2 months after stroke)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Early locomotor training
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Late locomotor training
Number of subjects: 408
Study: 19349671

Group type: EXPERIMENTAL
Intervention: Short 7-day GnRHa protocol
Number of subjects: 88

Group type: COMPARATOR
Intervention: GnRHa long protocol
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 88
Study: 16885576

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 4792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4792
Study: 15670429

Group type: EXPERIMENTAL
Intervention: Little by Little CD-ROM with reminder calls
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Little by Little CD-ROM without reminder calls
Number of subjects: 481

Group type: COMPARATOR
Intervention: Stress management CD-ROM (control condition)
Number of subjects: 481
Study: 11414674

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training (HI)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 503
Study: 9225876

Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 600 mg i.v. daily for 10 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8488368

Group type: EXPERIMENTAL
Intervention: Acetorphan
Number of subjects: 69

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 69
Study: 3624669

Group type: EXPERIMENTAL
Intervention: Active pyridostigmine (180 mg orally every 12 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Active pyridostigmine
Number of subjects: 20
Study: 29251296

Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problem List with nurse‐guided follow‐up (n=53)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care (n=57)
Number of subjects: 110
Study: 27565304

Group type: EXPERIMENTAL
Intervention: Psychologically-informed physiotherapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Current best care
Number of subjects: 138
Study: 25429523

Group type: EXPERIMENTAL
Intervention: Reduced visual acuity (VA) measured using a retroilluminated logMAR chart with tumbling‐E optotypes.
Number of subjects: 725423

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 725423

Group type: EXPERIMENTAL
Intervention: Urban vs rural comparison
Number of subjects: 725423

Group type: EXPERIMENTAL
Intervention: Projected cases of reduced VA
Number of subjects: 725423

Group type: EXPERIMENTAL
Intervention: Population density correlation
Number of subjects: 725423
Study: 23532240

Group type: EXPERIMENTAL
Intervention: EDTA chelation (3 g of disodium EDTA, 7 g of ascorbate, B vitamins, electrolytes, procaine, and heparin) administered via 40 infusions of a 500-mL solution over 30 weeks (weekly for 30 weeks, then 10 infusions 2 to 8 weeks apart)
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Placebo (500-mL solution) administered in the same regimen as the EDTA group
Number of subjects: 1708

Group type: EXPERIMENTAL
Intervention: EDTA chelation
Number of subjects: 1708

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1708
Study: 20135607

Group type: EXPERIMENTAL
Intervention: Clinical Trial Unit for Orthopaedics and Trauma Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training of supporting physicians through rotations in CHIR-Net
Number of subjects: 0
Study: 18761646

Group type: EXPERIMENTAL
Intervention: Metformin (MET), n = 15, dose: 1500 mg daily
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo, n = 13
Number of subjects: 28
Study: 17405254

Group type: EXPERIMENTAL
Intervention: Combination IGF‐I/GH therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo treatment (normal saline solution)
Number of subjects: 97
Study: 14527528

Group type: EXPERIMENTAL
Intervention: Negative fear information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive fear information
Number of subjects: 0
Study: 10767775

Group type: EXPERIMENTAL
Intervention: Denacen (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Calcort (reference formulation)
Number of subjects: 24
Study: 8665378

Group type: EXPERIMENTAL
Intervention: Permethrin impregnated bednets
Number of subjects: 48
Study: 1678757

Group type: EXPERIMENTAL
Intervention: Growth hormone injection pen
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional syringe method
Number of subjects: 20
Study: 6311000

Group type: EXPERIMENTAL
Intervention: Cefamandole plus amdinocillin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 50
Study: 11772821

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5% end‐tidal isoflurane, remifentanil up to 2 microg x kg(‐1) x min(‐1))
Number of subjects: 43

Group type: COMPARATOR
Intervention: Isoflurane (60% nitrous oxide, isoflurane up to 2% end‐tidal)
Number of subjects: 43
Study: 30171664

Group type: EXPERIMENTAL
Intervention: Immediate intensive treatment (eyedrops containing drugs from three different classes combined with 360° laser trabeculoplasty)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Commonly recommended stepped regimen (drug monotherapy in accordance with common glaucoma guidelines)
Number of subjects: 242
Study: 26823927

Group type: EXPERIMENTAL
Intervention: Care Plan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 40
Study: 24300226

Group type: EXPERIMENTAL
Intervention: Co-bedding group (cared for continuously in the same incubator or crib)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard care group (cared for in a separate incubator or crib)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Co-bedding group
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 134
Study: 22552037

Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil (800 mg/d)
Number of subjects: 2399

Group type: COMPARATOR
Intervention: Vegetable oil capsules without DHA
Number of subjects: 2399
Study: 20175903

Group type: EXPERIMENTAL
Intervention: Recruitment by letter on NHS headed note paper from General Practices
Number of subjects: 217

Group type: COMPARATOR
Intervention: Other recruitment methods (not specified)
Number of subjects: 217

Group type: COMPARATOR
Intervention: GP letters
Number of subjects: 217
Study: 18418808

Group type: EXPERIMENTAL
Intervention: High-volume training (HVT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-volume, high-intensity training (HIT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Taper period after both training types
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both training periods
Number of subjects: 10
Study: 15690862

Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo air/oxygen mixture
Number of subjects: 7
Study: 12394990

Group type: EXPERIMENTAL
Intervention: Perioperative customized exercise program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine perioperative care (Control)
Number of subjects: 28
Study: 10457270

Group type: COMPARATOR
Intervention: FokI polymorphism (ff genotype)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: FokI polymorphism (Ff and FF genotypes)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: FokI polymorphism
Number of subjects: 400
Study: 7607377

Group type: EXPERIMENTAL
Intervention: Endoscopic abdominal Burch colposuspension (via laparoscopy and 'retziusscopy')
Number of subjects: 20
Study: 2389061

Group type: EXPERIMENTAL
Intervention: Controlled release vaginal polymer pessary containing 10 mg prostaglandin E2 (PGE2), designed to release 0.6 mg per hour in vivo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: In vitro release profile of PGE2 from the polymer pessary
Number of subjects: 25
Study: 1015181

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5,000 U) administered 2 hours before surgery and every 8 hours for 6 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no heparin treatment)
Number of subjects: 99
Study: 30593689

Group type: EXPERIMENTAL
Intervention: BRP0.5: basal diet + 0.25 g BPO + 0.25 g RPO/kg diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BRP1.0: basal diet + 0.50 g BPO + 0.50 g RPO/kg diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BRP1.5: basal diet + 0.75 g BPO + 0.75 g RPO/kg diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BRP mixture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control: basal diet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 25224814

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m²) and the same RT dose (66-70 Gy/2 Gy fraction/5 fractions weekly)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Conventional radiotherapy (RT) (66-70 Gy/2 Gy fraction/5 fractions weekly)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Accelerated radiotherapy (RT) (66-70 Gy/2 Gy fraction/6 fractions weekly)
Number of subjects: 186
Study: 24484450

Group type: EXPERIMENTAL
Intervention: Salovum® (16 grams initially, followed by 8 g every 5 hours until recovery)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (ordinary egg yolk mixed in oral rehydration salts)
Number of subjects: 36
Study: 22357783

Group type: EXPERIMENTAL
Intervention: Revised pain protocol (RP group)
Number of subjects: 1728

Group type: COMPARATOR
Intervention: Control group (Ctrl group)
Number of subjects: 1728
Study: 20840339

Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate (PCC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 40
Study: 18580416

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 202
Study: 15728052

Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline (benzyl alcohol) as a preinjection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lidocaine mixed with propofol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (no bacteriostatic saline or lidocaine)
Number of subjects: 120
Study: 12966253

Group type: EXPERIMENTAL
Intervention: Treatment (not specified in the abstract)
Number of subjects: 61